| Summary: | Domperidone and metoclopramide are widely prescribed antiemetic drugs with distinct neurological side effects. The impact of P-glycoprotein (P-gp)-mediated efflux at the blood–brain barrier (BBB) on brain exposure and BBB permeation was compared in vitro and in vivo using positron emission tomography (PET) imaging in rats with the radiolabeled analogs [<sup>11</sup>C]domperidone and [<sup>11</sup>C]metoclopramide. In P-gp-overexpressing cells, the IC<sub>50</sub> of tariquidar, a potent P-gp inhibitor, was drastically different using [<sup>11</sup>C]domperidone (221 nM [198–248 nM]) or [<sup>11</sup>C]metoclopramide (4 nM [2–8 nM]) as the substrate. Complete P-gp inhibition led to a 1.8-fold higher increase in the cellular uptake of [<sup>11</sup>C]domperidone compared with [<sup>11</sup>C]metoclopramide (<i>p</i> < 0.0001). Brain PET imaging revealed that the baseline brain exposure (AUC<sub>brain</sub>) of [<sup>11</sup>C]metoclopramide was 2.4-fold higher compared with [<sup>11</sup>C]domperidone (<i>p</i> < 0.001), consistent with a 1.8-fold higher BBB penetration (AUC<sub>brain</sub>/AUC<sub>plasma</sub>). The maximal increase in the brain exposure (2.9-fold, <i>p</i> < 0.0001) and BBB penetration (2.9-fold, <i>p</i> < 0.0001) of [<sup>11</sup>C]metoclopramide was achieved using 8 mg/kg of tariquidar. In comparison, neither 8 nor 15 mg/kg of tariquidar increased the brain exposure of [<sup>11</sup>C]domperidone (<i>p</i> > 0.05). Domperidone is an avid P-gp substrate that was in vitro compared with metoclopramide. Domperidone benefits from a lower brain exposure and a limited risk for P-gp-mediated drug–drug interaction involving P-gp inhibition at the BBB.
|
|---|